Skip to main content
Inactivating MUTYH germline mutations in pediatric patients with high-grade midline gliomas.
CBIO-31MECHANISMS OF RESISTANCE TO EGFR INHIBITION REVEAL METABOLIC VULNERABILITIES IN HUMAN GBM.
Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs.
A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.
Targeting Wee1 for the treatment of pediatric high-grade gliomas.
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.
PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.
Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas.
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.